Study reveals how circulating tumour cells target organs
Regulator genes and proteins have been identified on circulating tumour cells in mice which allow them to target other organs in the body.
List view / Grid view
Regulator genes and proteins have been identified on circulating tumour cells in mice which allow them to target other organs in the body.
A new mechanism by which cancer cells become resistant to chemotherapy has been found which could lead to a new target for drugs.
A new study into the enzyme Cdc34 may make it possible to target the enzyme specifically to develop new cancer therapeutics.
A therapy has been developed which uses a synthetic RNA molecule developed to fight viruses to trigger an immune response against tumours in mice.
A study has found a selective inhibitor for an enzyme that allows cancer cells to mutate and become resistant to treatments.
A team has used viral gene editing and CRISPR to form a system that marks tumours for destruction, potentially improving immunotherapies.
A new algorithm has been developed which personalises which cancer mutations are best targets for immunotherapy.
New protein-painting technology could lead to developing cancer immunotherapy medicines that can be administered as a pill.
The researcher Sir Peter Ratcliffe and two others have been jointly awarded the Nobel Prize for Physiology or Medicine 2019.
Researchers have imaged an inflammation-related protein receptor on cell membranes which could inform future drug designs to prevent cell death.
Disruption of the MFF-VDAC1 complex could lead to a potential therapeutic target for cancer.
New research provides insights into how cancers can arise when DNA polymerase delta is not functioning properly.
A new process for identifying and biosynthesising drug candidates has been discovered by researchers at the Carl R Woese Institute for Genomic Biology.
A study using high-throughput screening has revealed some promising compounds that could be used in future cancer treatments.
A new method to reactivate 'tumour suppressor' genes switched off by cancer cells could lead to new targeted biotherapies for cancer.